News

BRAINBox Solutions Announces Appointment of Richard H. Noel as Chief Product and Commercial Officer

BRAINBox Solutions today announced the appointment of Richard H. Noel to the newly created position of Chief Product and Commercial Officer. Richard brings more than 10 years of experience in molecular and point-of-care diagnostics, at Roche Diagnostics, LumiraDx, and bioMérieux.

“Richard, whose expertise spans market analytics, global product management, and senior commercial leadership, has established a strong track record at leading diagnostics companies,” said Donna Edmonds, BRAINBox Solutions CEO. “He is well positioned to lead the commercial planning and launch for our BRAINBox TBI concussion diagnostic/prognostic tests.”

“BRAINBox has a unique opportunity to change the standard of care for concussion management with its BRAINBox TBI tests, the first objective tests for the diagnosis and risk of long-term complications,” said Mr. Noel. “The company has built an outstanding foundation with product and clinical development and strong relationships with key thought leaders in neurology and emergency medicine. I look forward to working with the team to bring these promising tests to clinicians and patients.”

Mr. Noel began his career in diagnostics at bioMérieux as a market analyst in the BioFire diagnostics unit, rising to Global Product Manager, where he served as global product leader for numerous syndromic molecular diagnostic panels, analyzers and software solutions. At Lumira, he served as Senior Director of Marketing, North America, where he led the marketing strategy and launch of the company’s novel SARS-CoV-2 Ag test during the Covid pandemic. He spearheaded the marketing strategy for the company’s North American point-of-care business, launching and scaling it from $0 to $440 million in revenue within 24 months. Following LumiraDx’s acquisition by Roche Diagnostics in 2024, he guided the full integration of the LumiraDx commercial business and roadmap.

Before entering the diagnostics industry, Mr. Noel taught honors physics, chemistry, and cognitive neuroscience. He holds a Master’s degree in Business and Biotechnology from the University of Utah and a Bachelor’s degree in Psychology from UC San Diego.

Read more here.

Recent News

11/10/2026

Luminoah Raises $25 Million Series B to Expand Access to Its FDA-Cleared Enteral Feeding System

Luminoah, a medical technology company modernizing enteral nutrition, today announced a $25 million Series B financing led by Sandbox Clinical Ventures, with participation from the Blue Venture Fund, GV (Google Ventures), Sands Capital, Texas Medical Center Venture Fund, the CU Healthcare Innovation Fund, the American Gastroenterological Association GI Opportunity Fund, and existing investors. The Series …

11/04/2026

$6 Million in Philanthropic Gifts Establishes UVA Biotech Innovation Fund

The University of Virginia Paul and Diane Manning Institute of Biotechnology received gifts totaling $6 million from philanthropists to establish the UVA Biotech Innovation Fund. This fund will provide long-term support for the UVA SPARK Innovative Medicines program, helping accelerate promising discoveries toward new treatments and cures. “The mission of the UVA Manning Institute of …

10/29/2026

ReAlta Life Sciences Launches KnowHIE, a New Online Educational Resource for Families of Babies Diagnosed with Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the launch of KnowHIE.com, a new educational website designed to help families and caregivers better understand neonatal hypoxic ischemic encephalopathy (HIE) …